Artemisinin Cocrystals for Bioavailability Enhancement. Part 2:


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
06 12 2021
Historique:
pubmed: 9 11 2021
medline: 15 3 2022
entrez: 8 11 2021
Statut: ppublish

Résumé

We report the evaluation and prediction of the pharmacokinetic (PK) performance of artemisinin (ART) cocrystal formulations, that is, 1:1 artemisinin/orcinol (ART-ORC) and 2:1 artemisinin/resorcinol (ART

Identifiants

pubmed: 34748332
doi: 10.1021/acs.molpharmaceut.1c00385
doi:

Substances chimiques

Artemisinins 0
artemisinin 9RMU91N5K2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4272-4289

Auteurs

Manreet Kaur (M)

Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, U.K.

Vanessa Yardley (V)

Department of Infection & Immunity, Faculty of Infectious & Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, U.K.

Ke Wang (K)

Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, U.K.

Jinit Masania (J)

Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, U.K.

Randolph R J Arroo (RRJ)

Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, U.K.

David B Turner (DB)

Certara UK Limited, Simcyp Division, Sheffield S1 2BJ, U.K.

Mingzhong Li (M)

Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, U.K.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH